Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial-Reference-Cited by-同舟云学术

Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial

Published:2022-09-28 Issue:6 Volume:36 Page:749-760
ISSN:1173-8804
Container-title:BioDrugs
language:en
Short-container-title:BioDrugs

Author:

Verschraegen Claire,Andric Zoran,Moiseenko Fedor,Makharadze Tamta,Shevnya Sergii,Oleksiienko Alona,Yañez Ruiz Eduardo,Kim SungHyun,Ahn KeumYoung,Park TaeHong,Park Sijin,Ju Hana,Ohe Yuichiro^ORCID

Funder

Celltrion, Inc.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine,Biotechnology

Link

https://link.springer.com/content/pdf/10.1007/s40259-022-00552-8.pdf

Reference42 articles.

1. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist. 2007;12(6):713–8. https://doi.org/10.1634/theoncologist.12-6-713.

2. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391–400. https://doi.org/10.1038/nrd1381.

3. European Medicines Agency. Avastin. Summary of product characteristics. 2022. https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf. Accessed 15 Jul 2022.

4. US Food and Drug Administration. Highlights of prescribing information, Avastin (bevacizumab). 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125085s337lbl.pdf. Accessed 15 Jul 2022.

5. Keating GM. Bevacizumab: a review of its use in advanced cancer. Drugs. 2014;74(16):1891–925. https://doi.org/10.1007/s40265-014-0302-9.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisions to the requirement of the Japanese clinical study data for biosimilar developments in Japan;Expert Opinion on Biological Therapy;2024-07-02

2. Survey of Data Package and Sample Size of Comparative Clinical Studies for Biosimilar Developments from PMDA Assessments;Pharmaceutical Medicine;2024-04-29

3. Clinical Benefit, Price, and Uptake for Cancer Biosimilars vs Reference Drugs in China;JAMA Network Open;2023-10-12

4. Real-World Clinical Outcomes of Bevacizumab-awwb Biosimilar versus Bevacizumab Reference Product in Patients with Metastatic Colorectal Cancer;BioDrugs;2023-09-25